184 related articles for article (PubMed ID: 26220768)
1. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Güldaş M; Altinkaya SÖ; Nergiz S; Demircan-Sezer S; Yüksel H
Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
[TBL] [Abstract][Full Text] [Related]
2. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Adali E; Yildizhan R; Kurdoglu M; Bugdayci G; Kolusari A; Sahin HG
Fertil Steril; 2010 Jul; 94(2):666-72. PubMed ID: 19368913
[TBL] [Abstract][Full Text] [Related]
3. Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.
de Mendonça-Louzeiro MR; Annichino-Bizzacchi JM; Benetti-Pinto CL
Fertil Steril; 2015 Aug; 104(2):467-73. PubMed ID: 26051101
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
[TBL] [Abstract][Full Text] [Related]
6. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
[TBL] [Abstract][Full Text] [Related]
7. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Altinkaya SÖ; Nergiz S; Küçük M; Yüksel H
Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():168-72. PubMed ID: 24642195
[TBL] [Abstract][Full Text] [Related]
8. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.
Mannerås-Holm L; Baghaei F; Holm G; Janson PO; Ohlsson C; Lönn M; Stener-Victorin E
J Clin Endocrinol Metab; 2011 Apr; 96(4):1068-76. PubMed ID: 21252248
[TBL] [Abstract][Full Text] [Related]
9. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
10. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.
Godtfredsen ACM; Sidelmann JJ; Gram JB; Andersen M; Glintborg D
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
12. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.
Hori Y; Gabazza EC; Yano Y; Katsuki A; Suzuki K; Adachi Y; Sumida Y
J Clin Endocrinol Metab; 2002 Feb; 87(2):660-5. PubMed ID: 11836301
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
15. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state.
Yildiz BO; Haznedaroğlu IC; Kirazli S; Bayraktar M
J Clin Endocrinol Metab; 2002 Aug; 87(8):3871-5. PubMed ID: 12161525
[TBL] [Abstract][Full Text] [Related]
16. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
17. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu I; Ersoz HO
Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
[TBL] [Abstract][Full Text] [Related]
18. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
Antovic JP; Rafik Hamad R; Antovic A; Blombäck M; Bremme K
Thromb Haemost; 2002 Oct; 88(4):644-7. PubMed ID: 12362237
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Küçük M; Altınkaya SÖ; Nergiz S; Sezer SD; Yüksel H; Bağlı İ; Yıldız G
Gynecol Endocrinol; 2014 Jun; 30(6):423-7. PubMed ID: 24628003
[TBL] [Abstract][Full Text] [Related]
20. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
